Apellis Pharma is Betting Big on Global Expansion for SYFOVRE; What Lies Ahead?

Apellis Pharmaceuticals, Inc., a biopharmaceutical company focused on C3 targeting therapies, reported a mixed set of results for the first quarter of 2025. The quarter was marked by both achievements and challenges across their product portfolio. Key products include SYFOVRE for geographic atrophy (GA) and EMPAVELI, targeting rare nephrology indications like C3G and IC-MPGN, the latter advancing toward possible FDA approval with a PDUFA date set for July 28.